Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Series A Common Stock, par value $0.0001 per share
-
Shares outstanding
-
31.3M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
11.7M
-
Shares change
-
-2.13M
-
Total reported value, excl. options
-
$89M
-
Value change
-
+$3.49M
-
Put/Call ratio
-
0.71
-
Number of buys
-
34
-
Number of sells
-
-40
-
Price
-
$7.62
Significant Holders of Sagimet Biosciences Inc. - Series A Common Stock, par value $0.0001 per share (SGMT) as of Q2 2025
101 filings reported holding SGMT - Sagimet Biosciences Inc. - Series A Common Stock, par value $0.0001 per share as of Q2 2025.
Sagimet Biosciences Inc. - Series A Common Stock, par value $0.0001 per share (SGMT) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.7M shares
of 31.3M outstanding shares and own 37.33% of the company stock.
Largest 10 shareholders include Woodline Partners LP (2.55M shares), Blue Owl Capital Holdings LP (1.33M shares), VANGUARD GROUP INC (1.15M shares), BAKER BROS. ADVISORS LP (953K shares), HHLR ADVISORS, LTD. (725K shares), Siren, L.L.C. (725K shares), UBS Group AG (573K shares), BlackRock, Inc. (483K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (413K shares), and READYSTATE ASSET MANAGEMENT LP (269K shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.